Skip to main content
SpringerLink
Log in

Pharmacokinetics of verapamil and its major metabolite, nor-verapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride

  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

The aim of this study was to investigate the pharmacokinetic changes of verapamil and its major metabolite, norverapamil, after oral administration of verapamil (10 mg/kg) in rabbits with slight, moderate and severe hepatic failure induced by carbon tetrachloride. The plasma verapamil concentrations in all groups of hepatic failure were significantly higher (p<0.01) than the control. However, the plasma norverapamil concentrations in severe hepatic failure were significantly higher (p<0.05) than the control. The peak concentrations (Cmax) and the areas under the plasma concentration-time curve (AUC) of verapamil in the rabbits were significantly (p<0.01) higher than the control. The absolute bioavailability (FA.B) and the relative bioavailability (FR.B) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively). Although the AUC and Cmax of its major metabolite, norverapamil, in slight, moderate hepatic failure were not significantly lower than the control, the metabolite-parent AUC ratio in all groups of hepatic failure was decreased significantly (p<0.05, in slight group; p<0.01, in moderate and severe group) than the control. This could be due to decrease in metabolism of verapamil in the liver because of suppressed hepatic function in the hepatic failure groups because verapamil is mainly metabolized in the liver. From our data, it would seem appropriate that in patients with liver disease, doses of verapamil should be decreased by degree of hepatic failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Eichelbaum, M., Remberg, E. G., Schomerus, M., and Dengler, H. J., The metabolism of D, L(14C) verapamil in man.Drug Metab. Dispos., 7, 145–148 (1979).

    PubMed  CAS  Google Scholar 

  • Eichelbaum, M., Albrecht, M., Kliems, G., Schafer, K., and Somogyi, A., Influence of mesocaval shunt or surgery on verapamil kinetics, bioavailability and response.Brit. J. Clin. Pharmacol., 10, 527–529 (1980).

    CAS  Google Scholar 

  • Eichelbaum, M., Mikus, G., and Vogelgesang, B., Pharmacokinetics of (+)-, (-)-and (±)-verapamil after intravenous administration.Brit. J. Clin. Pharmacol., 17, 453–458 (1984).

    CAS  Google Scholar 

  • Fleckenstein, A., Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.Ann. Rev. Pharmacol. Toxicol., 17, 149–166 (1977).

    Article  CAS  Google Scholar 

  • Freedman, S. B., Richmond, D. R., Ashley, J. J., and Kelly, D. T., Verapamil kinetics in normal subjects and patients with coronary artery spasm.Clin. Pharmacol. Ther., 30, 644–652 (1981).

    PubMed  CAS  Google Scholar 

  • Gould, B. A., Mann, S., Kieso, H., Bala Subramanian, V., and Raftery, E. B., The 24-hour ambulatory blood pressure profile with verapamil.Circulation, 65, 22–27 (1982).

    PubMed  CAS  Google Scholar 

  • Krecic-Shepard, M. E., Bamas, C. R., Slimko, J., and Schwartz, J. B., Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex-specific differences after oral administration of verapamil.Clin. Pharmacol. Then, 68, 286–292 (2000).

    Article  CAS  Google Scholar 

  • Lewis, G. R., Morley, K. D., Lewis, B. M., and Bones, P. J., The treatment of hypertension with verapamil.NZ. Medical J., 87, 351–354 (1978).

    CAS  Google Scholar 

  • Rocci, M. L., and Jusko, W. J., LAGRAN program for area and moments in pharmacokinetic analysis.Computer Programs in Biomedicine, 16, 203–209 (1983).

    Article  PubMed  Google Scholar 

  • Schomerus, M., Spiegelhaider, B., Stieren, B., and Eichelbaum, M., Physiologic disposition of verapamil in man.Cardiovasc. Res., 10, 605–612 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Schwartz, J. B., Abernethy, D. R., Taylor, A. A., and Mitchell, J. R., An investigation of the cause of accumulation of verapamil during regular dosing in patients.Brit. J. Clin. Pharmacol., 19, 512–516 (1985).

    CAS  Google Scholar 

  • Somogyi, A., Albrecht, M., Kliems, G., Schafer, K., and Eichelbaum, M., Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.Brit. J. Clin. Pharmacol., 12, 51–60 (1981).

    CAS  Google Scholar 

  • Woodcock, B. G., Rietbrock, I., Vohringer, H. F., and Rietbrock, N., Verapamil disposition in liver disease and intensive-care patients: Kinetics, clearance, and apparent blood flow relationships.Clin. Pharmacol. Ther., 29, 27–34 (1981).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chosun Nursing College, 280, Seosuk-Dong, Dong-Gu, Gwangju 501-825, Korea

    Jin Pil Burm

  2. College of Pharmacy, Chosun University, 501-759, Gwangju, Korea

    Jun Shik Choi & Jin Pil Burm

Authors
  1. Jun Shik Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Pil Burm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin Pil Burm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, J.S., Burm, J.P. Pharmacokinetics of verapamil and its major metabolite, nor-verapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. Arch Pharm Res 28, 483–487 (2005). https://doi.org/10.1007/BF02977680

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02977680

Key words

Search

Navigation